Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · IEX Real-Time Price · USD
6.10
-0.21 (-3.33%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Fulcrum Therapeutics Revenue
Fulcrum Therapeutics had revenue of $2.51M in the twelve months ending March 31, 2024, down -37.95% year-over-year. In the year 2023, Fulcrum Therapeutics had annual revenue of $2.81M, a decrease of -55.77%.
Revenue (ttm)
$2.51M
Revenue Growth
-37.95%
P/S Ratio
151.05
Revenue / Employee
$33,026
Employees
76
Market Cap
379.14M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
Dec 31, 2020 | 8.82M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.78B |
Anika Therapeutics | 169.26M |
Talkspace | 162.13M |
Editas Medicine | 69.41M |
MaxCyte | 44.05M |
AC Immune | 16.82M |
Precigen | 5.44M |
IGM Biosciences | 2.11M |
FULC News
- 7 weeks ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 - GlobeNewsWire
- 7 weeks ago - Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET - GlobeNewsWire
- 3 months ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET - GlobeNewsWire